louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05516238: Systematic Use of Telepsychiatry for Outpatients
Official title: Systematic Use of Telepsychiatry for Outpatients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Borderline Personality Disorder
Depressive Disorder
Ptsd
Anxiety Disorders
Lead sponsor: Psychiatric Research Unit, Region Zealand, Denmark
Sponsor class: OTHER
First posted: 2022-08-25
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Implementation and evaluation of video consultation in psychiatric outpatient treatment. The study will focus on patients' experiences regarding the use of VC. The study will also examine important aspects of the telepsychiatric consultation such as therapeutic alliance, consultation content, psychopathology and satisfaction levels compared to face-to-face consultations.


Eligibility criteria: Inclusion Criteria:

* age \> 18 years
* Danish-speaking.

Exclusion Criteria:

* Exclusion criteria included a diagnosis of schizophrenia or bipolar disorder, or suffering from substance abuse.
* Additionally, Participants in the VC group were excluded if they did not have a smartphone, tablet, laptop, or personal computer with a webcam.

Primary outcomes:
measure: The demand for video consultation (VC) in clinical practice.
timeFrame: One year
measure: Patients' therapeutic alliance, assessed by working alliance inventory- client version (WAI-C)
timeFrame: Two months.
measure: Patients' satisfaction, assessed by client satisfaction questionnaire 8 (CSQ-8)
timeFrame: Two months.
measure: Patients' Symptom level, assessed by Symptom Checklist -10 (SCL-10)
timeFrame: Two months.
measure: Patients' well-being, assessed by World Health Organisation- Five Well-Being Index (WHO-5)
timeFrame: Two months.
measure: Patients' function, assessed by Sheehan Disability Scale (SDS)
timeFrame: Two months.
measure: Patient recovery, assessed by INSPIRE
timeFrame: Two months.
measure: The implementation and integration of VC in clinical practice, as assessed by a checklist developed for the case managers (CM).
timeFrame: One year
measure: Patients' experiences regarding the use of VC
timeFrame: Two months
Secondary outcomes:
Other outcomes:
Locations:
city: Slagelse
country: Denmark
facility: Psychiatric research unit, Region Zealand,
Study officials:
References:
Clinical trial NCT01691638: Genetics of Periodontal Diseases in European Caucasians
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Periodontitis
Lead sponsor: University of Kiel
Sponsor class: OTHER
Collaborators: name: Interleukin Genetics, Inc.
First posted: 2012-09-25
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All study subjects will be selected from pre-existing patient databases in Germany and the Netherlands. All chronic periodontitis cases and controls will be subjects who were at least 35 years old at time of enrollment. Classification of chronic periodontitis will be based on extent of alveolar bone loss with consideration of tooth loss.

Brief summary: (A retrospective case control study to validate the association between Interleukin-1 gene variations and adult chronic periodontal disease in European Caucasians)


Eligibility criteria: Inclusion Criteria:

* Ethnicity: Dutch or German Caucasian

Exclusion Criteria:

* None (however, diabetics were excluded during original patient recruitment at several clinical sites).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04240938: Adult Dacryocystocele Among Patients With Epiphora
Official title: Adult Encysted Dacryocystocele: Prevalence Among Patients With Epiphora and Its Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lacrimal Passage Obstruction
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2020-01-27
Enrollment: 34
Sex: ALL
Minimum age (years): 19
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Adult Dacryocystocele
Primary purpose: TREATMENT

Brief summary: Patients with lacrimal dacryocystocele were chosen for the study. Dacryocystorhinostomy were done for them after their evaluation.

Detailed description: Evaluation for lacrimal passage in the included patients using syringing, probing and dye disappearance test. Dacryocystorhinostomy were done for all patients and followed up for at least 6 months.

Eligibility criteria: Inclusion Criteria:

* Lacrimal sac mucocele
* Acquired type

Exclusion Criteria:

* No previous lacrimal sac surgery
* Suspected lacrimal sac malignancy

Primary outcomes:
measure: Patency of the lacrimal passage
timeFrame: 2 weeks
measure: Disappearance of lacrimal sac swelling
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Faculty of Medicine
state: Minia
Study officials:
affiliation: Minia University
name: Mohamed F Ibrahiem, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05313438: The STIM-ADHF Study
Official title: Cardiac Pulmonary Nerve STIMulation in Acute Decompensated Heart Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Decompensated Heart Failure
Keywords: Neurostimulation
Contractility
Right Pulmonary Artery
Lead sponsor: Cardionomic Inc.
Sponsor class: INDUSTRY
First posted: 2022-04-06
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The STIM-ADHF Study is a multi-center, observational study to assess the performance and safety of the CPNS System in patients with ADHF.

Detailed description: The CPNS System is a neuromodulation system used to treat ADHF, a sudden or slow deterioration of chronic heart failure. The CPNS system is intended to provide acute (≤ 5 days) endovascular stimulation of the cardiac autonomic nerves in the right pulmonary artery (PA) in hospitalized ADHF patients. The system consists of an acute temporary neuromodulation stimulation catheter placed in the right pulmonary artery via venous access and a custom stimulator, denoiser, and associated cables. The CN2 Catheter is delivered to the right PA and provides an inotropic and/or lusitropic therapeutic effect by electrical stimulation to the terminal sympathetic nerve branches within the cardio-pulmonary plexus. The study will be conducted at up to 20 study sites worldwide. Up to 50 subjects who meet the eligibility criteria, will be enrolled, treated in-hospital with the Cardionomic CPNS System, monitored closely throughout the hospitalization and followed through 30 days post hospital discharge to evaluate the effect of the CPNS treatment.

Eligibility criteria: Inclusion Criteria:

* Admitted to the hospital or planned to be admitted with a principal diagnosis of acute decompensated heart failure
* BMI adjusted BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL
* LVEF ≤ 50%
* At least one sign/symptom of fluid overload
* At least one of the following:
* Inadequate diuretic response
* At least one sign or symptom of low perfusion

Exclusion Criteria:

* Received an inotrope during current hospitalization
* Requires mechanical support
* Cardiogenic shock or impending cardiogenic shock
* Multi-organ failure
* Systolic blood pressure \< 80mmHg or \> 140mmHg
* Symptomatic hypotension
* eGFR \< 25 mL/min/1.732
* Severe hepatic disease

Primary outcomes:
measure: Occurrence of related adverse events
timeFrame: Enrolment to 30 Days post hospital discharge
Secondary outcomes:
Other outcomes:
Locations:
city: Budapest
country: Hungary
facility: Semmelweis University, Heart and Vascular Center
city: Pécs
country: Hungary
facility: Hearth Faculty of Medicine, University of Pécs
city: Szeged
country: Hungary
facility: Szegedi Tudományegyetem ÁOK
city: Bielsko Biala
country: Poland
facility: American Heart of Poland
city: Banská Bystrica
country: Slovakia
facility: Stredoslovenský Ústav srdcových a Cievnych Chorȏb, a.s.
city: Bratislava
country: Slovakia
facility: CINRE s.r.o
Study officials:
References:
Clinical trial NCT00678938: Smoking Interventions in the General Population
Official title: General Population Based Interventions for Smokers Not Ready to Quit: Testing Smoking Reduction vs. Abstinence Oriented Computer Expert Systems
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Tobacco Smoking
Keywords: smoking reduction
smoking cessation
stages of change
expert system interventions
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2008-05-16
Enrollment: 1462
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The study takes up two problems: 1) Little research exists about general population interventions for smokers not ready to quit within the foreseeable future. 2) There is little evidence for smoking reduction as a behavioural goal in interventions. Interventions based on the Transtheoretical Model of Behavior Change (TTM) using computer expert-system technology yield delayed and smaller effects in smokers in the precontemplation stage of change compared to smokers in more advanced stages of change. Reducing the number of cigarettes smoked per day is currently discussed as an intermediate goal for this subgroup. Epidemiological and clinical studies revealed that smokers are able to maintain a substantial reduction. No undermining effects with respect to smoking cessation have been found. However, there are no studies that test the efficacy of behavioural interventions for smoking reduction using population based recruitment. Objectives: Testing the efficacy of TTM based interventions for general population smokers not intending to quit smoking, i.e. a smoking-reduction and a smoking-cessation tailored intervention using computerized expert-system technology.


Eligibility criteria: Inclusion Criteria:

* Daily smoking of 10 or more cigarettes
* No intention to quit within the next six month
* Age of 18 years and older
* valid telephone number

Exclusion Criteria:

- Insufficient german language and cognitive capabilities to complete the assessment

Primary outcomes:
measure: Point prevalence of tobacco abstinence
timeFrame: 24 hours, 7 days, 4 weeks, 6 months preceeding the 12 and 24 month follow-up assessments
Secondary outcomes:
measure: number of Cigarettes smoked per day
timeFrame: 4 weeks preceeding follow-up assessment
measure: number of quit and cutdown attempts
timeFrame: last 12 months preceeding follow-up assessment
measure: Stages of change progress
timeFrame: at 12 and 24 months follow-up
Other outcomes:
Locations:
Study officials:
affiliation: Ernst-Moritz-Arndt-University of Greifswald, Institute of Epidemiology and Social Medicine
name: Christian Meyer, Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Ernst-Moritz-Arndt-University of Greifswald, Institute of Epidemiology and Social Medicine
name: Ulrich John, Prof. Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01708538: The Effects of Corneal Collagen Cross-linking
Official title: Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Corneal Ectasia Disorders Including Keratoconus
Keywords: keratoconus, corneal collagen crosslinking, riboflavin, corneal ectasia
Lead sponsor: Rush Eye Associates
Sponsor class: OTHER
First posted: 2012-10-17
Enrollment: 30
Sex: ALL
Minimum age (years): 10
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The corneal collagen cross-linking treatment has been used with increasing success to treat corneal dystrophies such as "keratoconus." Recent advances have allowed different techniques for performing this cross-linking treatment. This study investigates the effects of corneal cross-linking using different surgical techniques.


Eligibility criteria: Inclusion Criteria:

* Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

Exclusion Criteria:

* Unwilling or unable to participate in trial

Primary outcomes:
measure: Visual acuity
timeFrame: 1 year
measure: Keratometry measurements
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Amarillo
country: United States
facility: Rush Eye Associates
state: Texas
Study officials:
References:
citation: Rush SW, Rush RB. Epithelium-off versus transepithelial corneal collagen crosslinking for progressive corneal ectasia: a randomised and controlled trial. Br J Ophthalmol. 2017 Apr;101(4):503-508. doi: 10.1136/bjophthalmol-2016-308914. Epub 2016 Jul 7.
Clinical trial NCT02357238: Genetics of Uveitis
Official title: Genetics of Uveitis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Uveitis
Infectious Uveitis
Keywords: Uveitis
Infectious
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2015-02-06
Enrollment: 1500
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Any patient able to sign an informed consent or child of age 6 with parental /guardian consent with the diagnosis of uveitis or infectious uveitis.

Brief summary: In order to improve the investigators knowledge about uveitis and the underlying mechanism of disease, the investigators propose collecting blood from patients with uveitis, isolating DNA and sequencing the DNA to identify genetic mutations or associations in these patients.


Eligibility criteria: Inclusion Criteria:

* Any patient above with the diagnosis of uveitis.
* Any patient with a diagnosis of infectious uveitis such as toxoplasmosis retinochoroiditis, herpes associated retinitis.

Exclusion Criteria:

* Patients who are unable to give consent
* Patients in whom an adequated blood sample can not be obtained.

Primary outcomes:
measure: Non infectious uveitis
timeFrame: 5 years
Secondary outcomes:
measure: Infectious uveitis
timeFrame: 5 years
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Sunil K. Srivastava, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00350038: Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
Official title: Investigations of the Effects of Aprovel, Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Dyslipidemia
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
Collaborators: name: Bristol-Myers Squibb
First posted: 2006-07-10
Enrollment: 60
Sex: ALL
Minimum age (years): 45
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.


Eligibility criteria: Inclusion Criteria:

* hypertensive + dyslipidemic + damaged endothelial function

Exclusion Criteria:

* hepatic and kidney damage,
* IDDM (Insulin Dependent Diabetes Mellitus)
* Freckson V type hyperlipoproteinaemia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Microvascular reactivity
Secondary outcomes:
measure: Reach of target blood pressure
measure: Measurements of safety laboratory parameters
Other outcomes:
Locations:
city: Budapest
country: Hungary
facility: Sanofi-aventis
Study officials:
affiliation: Sanofi-aventis, Hungary
name: László Erős, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06410638: Intercostal Muscle Oxygenation During Exercise Tests
Official title: Effect of Different Exercise Capacity Tests on Intercostal Muscle Oxygenation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Muscle Oxygenation
Keywords: exercise capacity test
muscle oxygenation
intercostal muscle
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2024-05-13
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy young adults

Brief summary: The aim of our study is to determine the effects of different exercise capacity tests on intercostal muscle oxygenation and to reveal the effect of changing accessory respiratory muscle oxygenation on exercise test success.

Detailed description: In the study, intercostal muscle oxygenation will be measured in different exercise capacity tests. A total of 32 healthy young women and men between the ages of 18-25 who meet the inclusion criteria and voluntarily agree to participate in the study will be included in the study. The cases will be randomized into 2 groups: Six minute walking test group and incremental shuttle walking test group. Heart rate, oxygen saturation, and fatigue levels will be measured with the modified Borg scale before and after the tests. During the tests, oxygen levels of the intercostal muscles will be monitored with the MOXY device. After sufficient wash out time, the groups will be crossed and different exercise tests will be applied to the cases. The result of our study will provide information about the use of intercostal muscles during different exercise tests. As a result of the study, results that can be interpreted for patient groups with circulatory system, respiratory system and physical limitations will be obtained.

Eligibility criteria: Inclusion Criteria:

* Being between the ages of 18-35
* Body Mass Index \&lt;25 kg/m²
* Participating in the study voluntarily

Exclusion Criteria:

* Being a smoker
* Presence of any systemic, orthopedic or cardiopulmonary disease that may prevent exercise tests
* Presence of any diagnosed respiratory, vascular and heart disease

Primary outcomes:
measure: Evaluation of Muscle Oxygenation of intercostal muscles
timeFrame: During intervention
Secondary outcomes:
measure: Forced expiratory pressure in one second
timeFrame: Baseline
measure: Evaluation of blood pressure
timeFrame: During the intervention
measure: Evaluation of heart rate
timeFrame: During the intervention
measure: Evaluation of oxygen saturation
timeFrame: During the intervention
measure: Forced vital capacity
timeFrame: Baseline
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: University of Health Sciences Turkey
Study officials:
References:
Clinical trial NCT00715338: Effects of Oxygen on Lung Tissue During Anesthesia
Official title: Effects of Oxygen on Lung Tissue During Anesthesia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Lung Injury, Acute
Keywords: Exhaled Breath Condensate
elective surgery
mechanical ventilation
Isofurans
thrombomodulin
requiring
mechanical
ventilation
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2008-07-15
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients scheduled for a routine surgical procedure

Brief summary: Collect exhaled breath condensates from patients scheduled for a routine surgical procedure before, during, and after surgery for measurements of IsoFs

Draw blood from patients scheduled for a routine surgical procedure before, during, and after surgery for measurements of serum thrombomodulin.

Detailed description: High concentrations of oxygen are routinely administered to patients undergoing routine surgical procedures even though it is highly likely, at least in patients with normal lung function, that this is unnecessary and in fact may be doing unnecessary harm. Therefore, we plan to assess whether there is any evidence of lung injury during surgery resulted from administration of high concentrations of oxygen by measuring Isofurans (IsoFs) in exhaled breath condensate. In our studies in mice that were exposed to high concentrations of oxygen we also found that circulating levels of thrombomodulin were increased. Thrombomodulin is present in endothelial cells and upon injury they release thrombomodulin into the circulation. Endothelial cell injury is known to occur in hyperoxic-induced lung injury. Therefore, in addition to measuring IsoFs in exhaled breath condensate we will also measure plasma concentrations of thrombomodulin as an indicator of endothelial injury.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologists (ASA) Class I-III.
* Patient is undergoing elective surgery requiring mechanical ventilation
* Patient is an adult, 18 - 80 years old.
* Subject has voluntarily signed and dated the informed consent document approved by the Institutional Review Board (IRB).

Exclusion Criteria:

* Surgical procedures boarded for less than 2 hours
* Current Smoker
* All Cardiac, Thoracic and/or Vascular surgeries involving the chest
* Patient unable to cooperate.
* Chronic airway diseases
* Asthma
* Medical contraindication to anesthetic technique (allergy, cardiac condition, neurologic condition, localized infection, bleeding disorder).
* Subjects who are pregnant.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: John A Barwise, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06553638: Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
Official title: Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Myeloproliferative Neoplasm
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2024-08-14
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a new diagnosis of MPN

Brief summary: 50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.


Eligibility criteria: Inclusion Criteria:

* MPN patient diagnosed at one of the participating centers
* over 18 yo

Exclusion Criteria:

* Not able to consent

Primary outcomes:
measure: b2mic decrease level between responders and non-responders
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: Chu Brest
Study officials:
References: